Evidence map›Paper›PMID 40694237›Full record

ArticleJournal of neuro-oncology2025

Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation.

E Iusupovskaia, N Isaev, A Antonian, A K Boromangnaeva, E Kuzmin, G Piavchenko, A Konovalov, G Pavlova, N Samoylenkova, P Timashev and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

E IusupovskaiaInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0009-0005-0327-7050
N IsaevInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0000-0002-8764-8891
A AntonianInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation.
A K BoromangnaevaInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation.
E KuzminDepartment of Human Anatomy and Histology, Institute of Clinical Medicine N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia.ORCID http://orcid.org/0000-0003-4098-1125
G PiavchenkoDepartment of Human Anatomy and Histology, Institute of Clinical Medicine N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia.ORCID http://orcid.org/0000-0001-7782-3468
A KonovalovInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0000-0002-0932-4752
G PavlovaBurdenko National Medical Research Center for Neurosurgery, Moscow, 125047, Russian Federation.
N SamoylenkovaBurdenko National Medical Research Center for Neurosurgery, Moscow, 125047, Russian Federation.ORCID http://orcid.org/0000-0002-5167-0253
P TimashevInstitute for Regenerative Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0000-0001-7773-2435
D TelyshevInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0000-0002-4221-9882
I UlasovInstitute for Regenerative Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation.ORCID http://orcid.org/0000-0002-0818-0363
Aleksandr MarkovInstitute for Bionic Technologies and Engineering, I.M. Sechenov First Moscow State Medical University, 8/2 Trubetskaya Str, Moscow, 119991, Russian Federation. markov_a_g@staff.sechenov.ru.ORCID http://orcid.org/0000-0002-3194-6064

Funding

Russian Science Foundation RSF No. 24-15-00496 dated May 6, 2024
6 · The paper itself

Abstract

purposeDrug resistance is a major challenge in the treatment of tumor diseases, especially in glioblastoma (GBM), where temozolomide (TMZ) plays a critical role. However, the development of resistance to TMZ occurs rapidly in more than half of the patients who initially respond to the drug. This highlights the need for novel approaches to overcome drug resistance and improve therapeutic outcomes in GBM treatment.

methodsIn our study, we combine TMZ treatment with wireless optoelectronics using advanced multilayered organic semiconductor (MOS) devices. These devices consist of a 200 nm thick stack of metal and p-n semiconducting organic nanocrystals. When illuminated in physiological solutions, these MOS devices charge up and convert light pulses into localized displacement currents, which are strong enough to electrically stimulate tumor cells at safe light intensities. Importantly, the freestanding MOS devices require no external wiring or bias and remain stable under physiological conditions. The semiconductor layers are created from common, non-toxic pigments using simple, scalable deposition methods.

resultsOur results demonstrate that this combination of TMZ and optoelectronic stimulation significantly enhances apoptosis in tumor cells, thereby improving the effectiveness of TMZ in treating glioblastoma.

conclusionhis research suggests that the integration of wireless optoelectronic stimulation with TMZ treatment offers a promising strategy to overcome drug resistance in GBM. The use of MOS devices enhances the therapeutic effect of TMZ and could lead to better treatment outcomes for patients with glioblastoma.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsGlioblastomaTemozolomideWireless TechnologyApoptosisCell Line, TumorHumansSemiconductorsAntineoplastic Agents, AlkylatingTemozolomideBioelectronicsGlioblastomaOrganic semiconductorsTemozolomide therapyWireless stimulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.